Additional Study Information: This is a research study to test the effectiveness of ICT-107, an experimental drug, with the standard of care (SOC) for treatment of glioblastoma compared to enriched blood cells (PBMC) with the SOC. The study will enroll 400 subjects age 18 years and older with newly diagnosed glioblastoma. Following an initial SOC radiation treatment, patients will be randomly assigned in a 1:1 ratio to receive either the ICT-107 with SOC or PBMC with SOC. Several survival rates will be used to determine the effectiveness of the new drug. Given the limited success of the current standard of care, ICT-107 has the potential for improving the outcome of patients with glioblastoma.